The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis

British Journal of Dermatology

Volumn 159, Issue 2, 2008, Pages 473-475

  Hofbauer, G F L ^a   Marcollo Pini, A ^a   Corsenca, A ^b   Kistler, A D ^b   French, L E ^a   Wuthrich R P ^b   Serra, A L ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Angiofibroma; MTOR; Rapamycin; Tuberous sclerosis

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ADOLESCENT; ANGIOMYOLIPOMA; ARTICLE; BLEEDING; CASE REPORT; DRUG SUBSTITUTION; FACIAL ANGIOFIBROMA; FEMALE; HEMANGIOFIBROMA; HEMATURIA; HUMAN; KIDNEY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; NEPHRECTOMY; NONSENSE MUTATION; PAPULE; PRIORITY JOURNAL; RASH; TUBEROUS SCLEROSIS;

ADOLESCENT; ANGIOFIBROMA; ANTIBIOTICS, ANTINEOPLASTIC; FACIAL NEOPLASMS; FEMALE; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SIROLIMUS; SKIN NEOPLASMS; TUBEROUS SCLEROSIS;

EID: 47549093135     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2008.08677.x     Document Type: Article

References (20)

1. Osborne JP, Fryer A, Webb D. Epidemiology of tuberous sclerosis. Ann NY Acad Sci 1991 615 : 125 7.
2. van Slegtenhorst M, de Hoogt R, Hermans C et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997 277 : 805 8.
3. European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993 75 : 1305 15.
4. Inoki K, Li Y, Zhu T et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002 4 : 648 57.
5. Potter CJ, Pedraza LG, Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol 2002 4 : 658 65.
6. Gao X, Zhang Y, Arrazola P et al. Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat Cell Biol 2002 4 : 699 704.
7. Schwartz RA, Fernandez G, Kotulska K et al. Tuberous sclerosis complex: advances in diagnosis, genetics, and management. J Am Acad Dermatol 2007 57 : 189 202.
8. Corsenca A, Aebersold F, Moch H et al. Combined nephrectomy and preemptive renal transplantation in a tuberous sclerosis patient with angiomyolipoma, renal carcinoma and life-threatening abdominal haemorrhages. Nephrol Dial Transplant 2007 22 : 3330 3.
9. Kwiatkowski DJ, Zhang H, Bandura JL et al. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum Mol Genet 2002 11 : 525 34.
10. Kenerson HL, Aicher LD, True LD et al. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res 2002 62 : 5645 50.
11. Au KS, Williams AT, Roach ES et al. Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States. Genet Med 2007 9 : 88 100.
12. Dabora SL, Jozwiak S, Franz DN et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet 2001 68 : 64 80.
13. Brugarolas JB, Vazquez F, Reddy A et al. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 2003 4 : 147 58.
14. El-Hashemite N, Walker V, Zhang H et al. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. Cancer Res 2003 63 : 5173 7.
15. Del Bufalo D, Ciuffreda L, Trisciuoglio D et al. Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 2006 66 : 5549 54.
16. Frost P, Moatamed F, Hoang B et al. In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood 2004 104 : 4181 7.
17. Franz DN, Leonard J, Tudor C et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006 59 : 490 8.
18. Herry I, Neukirch C, Debray MP et al. Dramatic effect of sirolimus on renal angiomyolipomas in a patient with tuberous sclerosis complex. Eur J Intern Med 2007 18 : 76 7.
19. Huber S, Bruns CJ, Schmid G et al. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int 2007 71 : 771 7.
20. Taille C, Debray MP, Crestani B. Sirolimus treatment for pulmonary lymphangioleiomyomatosis. Ann Intern Med 2007 146 : 687 8.